|
1
|
Ahmadian M, Suh JM, Hah N, Liddle C,
Atkins AR, Downes M and Evans RM: PPARγ signaling and metabolism:
The good, the bad and the future. Nat Med. 19:557–566. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Willson TM, Lambert MH and Kliewer SA:
Peroxisome proliferator-activated receptor gamma and metabolic
disease. Annu Rev Biochem. 70:341–367. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grygiel-Górniak B: Peroxisome
proliferator-activated receptors and their ligands: Nutritional and
clinical implications-a review. Nutr J. 13:172014. View Article : Google Scholar
|
|
4
|
Tyagi S, Gupta P, Saini AS, Kaushal C and
Sharma S: The peroxisome proliferator-activated receptor: A family
of nuclear receptors role in various diseases. J Adv Pharm Technol
Res. 2:236–240. 2011. View Article : Google Scholar
|
|
5
|
Janani C and Ranjitha Kumari BD: PPAR
gamma gene-a review. Diabetes Metab Syndr. 9:46–50. 2015.
View Article : Google Scholar
|
|
6
|
Braissant O, Foufelle F, Scotto C, Dauça M
and Wahli W: Differential expression of peroxisome
proliferator-activated receptors (PPARs): Tissue distribution of
PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology.
137:354–366. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Auboeuf D, Rieusset J, Fajas L, Vallier P,
Frering V, Riou JP, Staels B, Auwerx J, Laville M and Vidal H:
Tissue distribution and quantification of the expression of mRNAs
of peroxisome proliferator-activated receptors and liver X
receptor-alpha in humans: No alteration in adipose tissue of obese
and NIDDM patients. Diabetes. 46:1319–1327. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tachibana K, Yamasaki D, Ishimoto K and
Doi T: The role of PPARs in cancer. PPAR Res. 2008.102737:2008.
|
|
9
|
Koeffler HP: Peroxisome
proliferator‑activated receptor gamma and cancers. Clin Cancer Res.
9:1–9. 2003.PubMed/NCBI
|
|
10
|
Bermúdez V, Finol F, Parra N, Parra M,
Pérez A, Peñaranda L, Vílchez D, Rojas J, Arráiz N and Velasco M:
PPAR-gamma agonists and their role in type 2 diabetes mellitus
management. Am J Ther. 17:274–283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Larsen TM, Toubro S and Astrup A:
PPARgamma agonists in the treatment of type II diabetes: Is
increased fatness commensurate with long‑term efficacy? Int J Obes
Relat Metab Disord. 27:147–161. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim HI and Ahn YH: Role of peroxisome
proliferator-activated receptor-gamma in the glucose-sensing
apparatus of liver and beta-cells. Diabetes. 53(Suppl 1): S60–S65.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blanquicett C, Roman J and Hart CM:
Thiazolidinediones as anti-cancer agents. Cancer Ther. 6:25–34.
2008.PubMed/NCBI
|
|
14
|
Joshi H, Pal T and Ramaa CS: A new dawn
for the use of thiazolidinediones in cancer therapy. Expert Opin
Investig Drugs. 23:501–510. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moore KJ, Rosen ED, Fitzgerald ML, Randow
F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman
BM and Freeman MW: The role of PPAR-gamma in macrophage
differentiation and cholesterol uptake. Nat Med. 7:41–47. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Villacorta L, Schopfer FJ, Zhang J,
Freeman BA and Chen YE: PPARgamma and its ligands: Therapeutic
implications in cardiovascular disease. Clin Sci (Lond).
116:205–218. 2009. View Article : Google Scholar
|
|
17
|
Schopfer FJ, Lin Y, Baker PR, Cui T,
Garcia-Barrio M, Zhang J, Chen K, Chen YE and Freeman BA:
Nitrolinoleic acid: An endogenous peroxisome proliferator-activated
receptor gamma ligand. Proc Natl Acad Sci USA. 102:2340–2345. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Behl T, Kaur I, Goel H and Kotwani A:
Implications of the endogenous PPAR-gamma ligand,
15-deoxy-delta-12, 14-pros-taglandin J2, in diabetic retinopathy.
Life Sci. 153:93–99. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Viswakarma N, Jia Y, Bai L, Vluggens A,
Borensztajn J, Xu J and Reddy JK: Coactivators in PPAR-regulated
gene expression. PPAR Res. 2010:2010. View Article : Google Scholar
|
|
20
|
Berger J and Moller DE: The mechanisms of
action of PPARs. Annu Rev Med. 53:409–435. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi C, Zhu Y and Reddy JK: Peroxisome
proliferator-activated receptors, coactivators, and downstream
targets. Cell Biochem Biophys. 32:Spring;187–204. 2000. View Article : Google Scholar
|
|
22
|
Bedford MT and Clarke SG: Protein arginine
methylation in mammals: Who, what, and why. Mol Cell. 33:1–13.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Blanc RS and Richard S: Arginine
methylation: The coming of age. Mol Cell. 65:8–24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bedford MT: Arginine methylation at a
glance. J Cell Sci. 120:4243–4246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jain K, Jin CY and Clarke SG: Epigenetic
control via allosteric regulation of mammalian protein arginine
methyltransferases. Proc Natl Acad Sci USA. 114:10101–10106. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boulanger MC, Liang C, Russell RS, Lin R,
Bedford MT, Wainberg MA and Richard S: Methylation of Tat by PRMT6
regulates human immunodeficiency virus type 1 gene expression. J
Virol. 79:124–131. 2005. View Article : Google Scholar :
|
|
27
|
Frankel A, Yadav N, Lee J, Branscombe TL,
Clarke S and Bedford MT: The novel human protein arginine
N-methyltransferase PRMT6 is a nuclear enzyme displaying unique
substrate specificity. J Biol Chem. 277:3537–3543. 2002. View Article : Google Scholar
|
|
28
|
Guccione E, Bassi C, Casadio F, Martinato
F, Cesaroni M, Schuchlautz H, Lüscher B and Amati B: Methylation of
histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually
exclusive. Nature. 449:933–937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hyllus D, Stein C, Schnabel K, Schiltz E,
Imhof A, Dou Y, Hsieh J and Bauer UM: PRMT6-mediated methylation of
R2 in histone H3 antagonizes H3 K4 trimethylation. Genes Dev.
21:3369–3380. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
El-Andaloussi N, Valovka T, Toueille M,
Steinacher R, Focke F, Gehrig P, Covic M, Hassa PO, Schär P,
Hübscher U and Hottiger MO: Arginine methylation regulates DNA
polymerase beta. Mol Cell. 22:51–62. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim SN, Choi HY, Lee W, Park GM, Shin WS
and Kim YK: Sargaquinoic acid and sargahydroquinoic acid from
Sargassum yezoense stimulate adipocyte differentiation through
PPARalpha/gamma activation in 3T3-L1 cells. FEBS Lett.
582:3465–3472. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
33
|
Eram MS, Shen Y, Szewczyk M, Wu H,
Senisterra G, Li F, Butler KV, Kaniskan HÜ, Speed BA, Dela Seña C,
et al: A potent, selective, and cell-active inhibitor of human type
I protein arginine methyltransferases. ACS Chem Biol. 11:772–781.
2016. View Article : Google Scholar
|
|
34
|
Yang Y and Bedford MT: Protein arginine
methyltransferases and cancer. Nat Rev Cancer. 13:37–50. 2013.
View Article : Google Scholar
|
|
35
|
Cohen RN: Nuclear receptor corepressors
and PPARgamma. Nucl Recept Signal. 4:e0032006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van Beekum O, Fleskens V and Kalkhoven E:
Posttranslational modifications of PPAR-gamma: Fine-tuning the
metabolic master regulator. Obesity (Silver Spring). 17:213–219.
2009. View Article : Google Scholar
|
|
37
|
Brunmeir R and Xu F: Functional regulation
of PPARs through post‑translational modifications. Int J Mol Sci.
19:2018. View Article : Google Scholar
|
|
38
|
Quinn CE, Hamilton PK, Lockhart CJ and
McVeigh GE: Thiazolidinediones: Effects on insulin resistance and
the cardiovascular system. Br J Pharmacol. 153:636–645. 2008.
View Article : Google Scholar
|
|
39
|
Hauner H: The mode of action of
thiazolidinediones. Diabetes Metab Res Rev. 18(Suppl 2): S10–S15.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rizos CV, Elisaf MS, Mikhailidis DP and
Liberopoulos EN: How safe is the use of thiazolidinediones in
clinical practice? Expert Opin Drug Saf. 8:15–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nesto RW, Bell D, Bonow RO, Fonseca V,
Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith
S, et al: Thiazolidinedione use, fluid retention, and congestive
heart failure: A consensus statement from the American Heart
Association and American Diabetes Association. Diabetes Care.
27:256–263. 2004. View Article : Google Scholar
|
